GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxart Inc (NAS:VXRT) » Definitions » Cyclically Adjusted PB Ratio

Vaxart (Vaxart) Cyclically Adjusted PB Ratio : 0.10 (As of Jun. 01, 2024)


View and export this data going back to 1990. Start your Free Trial

What is Vaxart Cyclically Adjusted PB Ratio?

As of today (2024-06-01), Vaxart's current share price is $0.8229. Vaxart's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $8.20. Vaxart's Cyclically Adjusted PB Ratio for today is 0.10.

The historical rank and industry rank for Vaxart's Cyclically Adjusted PB Ratio or its related term are showing as below:

VXRT' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.17   Max: 0.51
Current: 0.1

During the past years, Vaxart's highest Cyclically Adjusted PB Ratio was 0.51. The lowest was 0.01. And the median was 0.17.

VXRT's Cyclically Adjusted PB Ratio is ranked better than
87.61% of 654 companies
in the Biotechnology industry
Industry Median: 1.745 vs VXRT: 0.10

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Vaxart's adjusted book value per share data for the three months ended in Mar. 2024 was $0.315. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $8.20 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vaxart Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Vaxart's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxart Cyclically Adjusted PB Ratio Chart

Vaxart Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.22 0.39 0.08 0.06

Vaxart Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.07 0.08 0.06 0.16

Competitive Comparison of Vaxart's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Vaxart's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaxart's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxart's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Vaxart's Cyclically Adjusted PB Ratio falls into.



Vaxart Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Vaxart's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.8229/8.2
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxart's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Vaxart's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.315/131.7762*131.7762
=0.315

Current CPI (Mar. 2024) = 131.7762.

Vaxart Quarterly Data

Book Value per Share CPI Adj_Book
201406 27.233 100.560 35.687
201409 24.412 100.428 32.032
201412 25.823 99.070 34.348
201503 25.523 99.621 33.761
201506 19.801 100.684 25.916
201509 18.079 100.392 23.731
201512 16.370 99.792 21.617
201603 15.002 100.470 19.677
201606 13.152 101.688 17.043
201609 10.419 101.861 13.479
201612 7.971 101.863 10.312
201703 6.888 102.862 8.824
201706 5.322 103.349 6.786
201709 3.956 104.136 5.006
201712 3.074 104.011 3.895
201803 4.356 105.290 5.452
201806 3.130 106.317 3.880
201809 2.239 106.507 2.770
201812 1.574 105.998 1.957
201903 1.508 107.251 1.853
201906 1.004 108.070 1.224
201909 0.409 108.329 0.498
201912 0.268 108.420 0.326
202003 0.435 108.902 0.526
202006 0.419 108.767 0.508
202009 1.203 109.815 1.444
202012 1.119 109.897 1.342
202103 1.494 111.754 1.762
202106 1.627 114.631 1.870
202109 1.636 115.734 1.863
202112 1.493 117.630 1.673
202203 1.322 121.301 1.436
202206 1.132 125.017 1.193
202209 0.953 125.227 1.003
202212 0.824 125.222 0.867
202303 0.662 127.348 0.685
202306 0.560 128.729 0.573
202309 0.470 129.860 0.477
202312 0.377 129.419 0.384
202403 0.315 131.776 0.315

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vaxart  (NAS:VXRT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Vaxart Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Vaxart's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaxart (Vaxart) Business Description

Industry
Traded in Other Exchanges
Address
170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
Executives
W. Mark Watson director 324 S. HYDE PARK AVENUE, STE 350, TAMPA FL 33606
Phillip E Lee officer: Chief Financial Officer C/O VAXART, INC., 170 HARBOR WAY, STE. 300, SOUTH SAN FRANCISCO CA 94080
Elaine J Heron director 6 STONEGATE RD, PONTOLA VALLEY CA 94028
Fuad Ahmad officer: Interim CFO 461 SOUTH MILPITAS BLVD., MILPITAS CA 95035
Edward B Berg officer: SVP, General Counsel C/O VAXART, INC., 170 HARBOR WAY, STE. 300, SOUTH SAN FRANCISCO CA 94080
Robert A. Yedid director C/O LIFESCI ADVISORS, 250 WEST 55TH STREET, SUITE 3401, NEW YORK NY 10019
Margaret Echerd officer: VP, Corporate Controller, PAO 3585 MONROE STREET, SANTA CLARA CA 95051
James F. Cummings officer: Chief Medical Officer 1312 BEACHVIEW ROAD, ANNAPOLIS MD 21403
Julie M Cherrington director 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Sean Tucker officer: Chief Scientific Officer 385 OYSTER POINT BLVD., SUITE 9A, SOUTH SAN FRANCISCO CA 94080
Wouter Latour director, officer: President and Chief Executive 385 OYSTER POINT BLVD., SUITE 9A, SOUTH SAN FRANCISCO CA 94080
David E. Wheadon director C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Karen J Wilson director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Todd C Davis director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037